A phase III trial confirmed that weekly cisplatin, epirubicin, and paclitaxel achieved significantly higher pCR rates than triweekly epirubicin and paclitaxel in locally advanced breast cancer, particularly in ER-negative and HER2-positive cases, though with increased toxicity (Frasci et al., 2006). This evidence concerns the gene ERBB2 and breast carcinoma.